SCHEMBL4472285

SCHEMBL4472285

Cc1c(C)c2c(c(C)c1O)CCC1(CC1)O2

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 2/20 0.61
TSHR P16473 2/20 0.61
PTGS1 P23219 1/20 0.61
PTGS2 P35354 1/20 0.61
CYP1A2 P05177 1/20 0.61
MAPT P10636 3/20 0.48
LMNA P02545 3/20 0.48
USP2 O75604 2/20 0.48
CYP2C9 P11712 2/20 0.48
KMT2A Q03164 2/20 0.48
MEN1 O00255 1/20 0.48
GSTP1 P09211 1/20 0.48
TTPA P49638 1/20 0.48
THRB P10828 1/20 0.48
CYP2C19 P33261 1/20 0.48
NR1I2 O75469 2/20 0.47
ALOX5 P09917 5/20 0.43
CYP4F2 P78329 1/20 0.41
TP53 P04637 1/20 0.39
ALOX15 P16050 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4471043 0.93 CYP3A4 (0.58) CYP3A4TSHRPTGS1PTGS2CYP1A2
SCHEMBL4427867 0.81 CYP3A4 (0.62) CYP3A4TSHRPTGS1PTGS2CYP1A2
SCHEMBL9090014 0.80 CYP3A4 (0.60) CYP3A4TSHRPTGS1PTGS2CYP1A2
SCHEMBL11703829 0.79 CYP3A4 (0.55) CYP3A4TSHRPTGS1PTGS2CYP1A2
SCHEMBL13080852 0.79 CYP3A4 (0.55) CYP3A4TSHRPTGS1PTGS2CYP1A2
SCHEMBL20822168 0.79 CYP3A4 (0.55) CYP3A4TSHRPTGS1PTGS2CYP1A2
SCHEMBL13081185 0.79 CYP3A4 (0.59) CYP3A4TSHRPTGS1PTGS2CYP1A2
SCHEMBL19084671 0.79 CYP3A4 (0.59) CYP3A4TSHRPTGS1PTGS2CYP1A2
SCHEMBL2176872 0.78 NR1I2 (0.61) CYP3A4TSHRPTGS1PTGS2CYP1A2
SCHEMBL4462709 0.78 CYP3A4 (0.43) CYP3A4TSHRPTGS1PTGS2CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7576094-B2 Spiro derivatives as lipoxygenase inhibitors ELI LILLY AND COMPANY (US) 2009-08-18 US claimed
US-20060128790-A1 Spiro derivatives as lipoxygenase inhibitors GALILEO PHARMACEUTICALS, INC. 2006-06-15 US claimed
US-7576094-B2 Spiro derivatives as lipoxygenase inhibitors ELI LILLY AND COMPANY (US) 2009-08-18 US disclosed
US-7576094-B2 Spiro derivatives as lipoxygenase inhibitors ELI LILLY AND COMPANY (US) 2009-08-18 US disclosed
US-7576094-B2 Spiro derivatives as lipoxygenase inhibitors ELI LILLY AND COMPANY (US) 2009-08-18 US disclosed
EP-1836183-A2 SPIRO DERIVATIVES AS LIPOXYGENASE INHIBITORS Galileo Pharmaceuticals, Inc. (US) 2007-09-26 EP disclosed
WO-2006065686-A2 SPIRO DERIVATIVES AS LIPOXYGENASE INHIBITORS GALILEO PHARMACEUTICALS, INC. (US) 2006-06-22 WO disclosed
US-20060128790-A1 Spiro derivatives as lipoxygenase inhibitors GALILEO PHARMACEUTICALS, INC. 2006-06-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060128790-A1 Spiro derivatives as lipoxygenase inhibitors ALOX15B, ALOX5, ALOX15 CYP3A4 317/4885TSHR 2301/4885PTGS1 24/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.